Loading…
On 3 September 2026 the US Food and Drug Administration approved Zanvastro (zilganersen), the first and only disease-modifying treatment for Alexander disease.
It is approved for both paediatric and adult patients and is made by Ionis Pharmaceuticals.
Zanvastro is an RNA-targeted medicine that reduces production of glial fibrillary acidic protein (GFAP), the protein whose build-up drives the disease.
It is given as a 50 mg intrathecal injection once a quarter.
Ionis set the list price at $285,000 per dose — about $1.14 million a year at quarterly dosing.
Instead of blocking a protein after it is made, an antisense oligonucleotide binds the messenger RNA that codes for it, so less of the protein is produced. In Alexander disease the target is GFAP mRNA.
Simple Analogy: Editing the order slip instead of throwing away the finished dish.
| Form | Typical onset | Characteristic features |
|---|---|---|
| Neonatal | Within the first month of life | Severe intellectual disability and developmental delay, hydrocephalus, seizures |
| Infantile (most common) | Before age 2 | Megalencephaly (enlarged brain and head), seizures, spasticity, intellectual disability, developmental delay |
| Juvenile | Later childhood | Speech abnormalities, swallowing difficulty, seizures, ataxia |
| Adult | Adulthood | Speech and swallowing problems, seizures, poor coordination |
The American regulator for drugs, biologics, medical devices and food safety; its approvals are widely used as a benchmark by other regulators, including for rare disease therapies.
India's national drug regulator under the Ministry of Health and Family Welfare, headed by the Drugs Controller General of India; it approves new drugs and clinical trials in India.
To lower the cost of rare disease treatment through indigenous research and local production, and to improve screening, prevention and treatment access.
Key: Groups rare diseases into three categories; provides financial support of up to Rs 50 lakh per patient — for Group 1 one-time treatments through the Umbrella Scheme of Rashtriya Arogya Nidhi, and for patients of any category treated at a notified Centre of Excellence. Support extends to about 40% of the population eligible under Ayushman Bharat PM-JAY, and the policy provides for Centres of Excellence and Nidan Kendras for genetic testing and counselling.
Nusinersen (Spinraza), also from Ionis, treats spinal muscular atrophy by the same antisense route — both are intrathecal RNA-targeted medicines for neurological disease.
Ultra-rare disease therapies carry very high per-patient prices because development costs are spread over tiny patient populations, raising access and reimbursement questions worldwide.
Leukodystrophies are genetic myelin disorders; multiple sclerosis is an acquired demyelinating disease — the distinction is a standard exam contrast.
Most Alexander disease mutations are de novo rather than inherited, which is why family history is often absent.
GS Paper 3 > Science and Technology: Biotechnology, Health; GS Paper 2 > Issues Relating to Health
General Awareness > Science, Health and Current Events
A group of genetic disorders that damage the white matter of the brain by affecting the myelin sheath.
Abnormal clumps of protein that accumulate in the brain in Alexander disease.
Glial fibrillary acidic protein; the gene mutation causing its accumulation is the underlying cause of most Alexander disease cases.
Injection into the cerebrospinal fluid space around the spinal cord, used to deliver drugs to the central nervous system.